Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (20 Mio. €): Personalisierte Prävention für koronare Herzkrankheit Hor 01.01.2020 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Personalisierte Prävention für koronare Herzkrankheit

European Coronary Heart Disease (CHD) burden is unsustainable. Better risk stratification tools and personalized care of patients are needed for reducing morbidity and mortality of CHD and the associated economic burden. To this end we have planned to shape and implement a personalized secondary prevention program for patients with established CHD. This precision strategy will be tested in a prospective trial, the CoroPrevention Trial, a central element of our proposal. We aim to significantly reduce the numbers of coronary events by using outcome risk- and patient characteristics- guided prevention in CHD patients. 1. Prospectively evaluate clinical utility of personalized prevention in CHD 2. Evaluate health economic and social benefits of the personalized prevention in CHD 3. Discover predictive markers of drug treatment response in CHD 4. Improve current ESC guidelines based on RCT validated clinical data 5. Disseminate the refined prevention program to the attention of practitioners, patients, health care payers and policy makers This program will establish a new economically sustainable personalized treatment practice applicable throughout Europe particularly to those regions where CHD prevention needs upgrading. The used protocols and technologies will carefully assessed by NICE using their standard evaluation methods that will allow independent expert opinions for different European authorities and decision makers. These opinion statements will further be supported by full Health Economics analyses of CoroPrevention Trial.


Geförderte Unternehmen:

Firmenname Förderungssumme
Associação para Investigação e Desenvolvimento da Faculdade de Medicina 0,00 €
Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) 221.750 €
Centrum Medycznego Ksztalcenia Podyplomowego 602.778 €
Charite - Universitaetsmedizin Berlin 446.250 €
Faculdade de Medicina da Universidade de Lisboa 687.800 €
HUS-Yhtyma 1.115.275 €
Idryma Iatroviologikon Ereunon Akademias Athinon 844.546 €
Institut National de la Sante et de la Recherche Medicale 149.169 €
Irccs Azienda Ospedaliera Metropolitana 44.615 €
Lakka Health Oy 514.500 €
Lakka Technologies Oy 0,00 €
Multimedica S.p.A. 762.939 €
National Institute for Health and Care Excellence 103.750 €
Optimapharm Nordic Oy 1.116.965 €
Oulun Yliopisto 956.455 €
Ruprecht-Karls-Universitaet Heidelberg 1.209.720 €
SE de Cardiologie 603.750 €
SGS Analytics Germany GmbH 791.875 €
Synlab Holding Deutschland GmbH 7.000,00 €
Tampereen Ammattikorkeakoulu Oy 0,00 €
Tampereen Korkeakoulusaatio sr 3.312.690 €
The University of Sheffield 639.000 €
Universiteit Hasselt 1.722.500 €
Uniweb 2.157.064 €
Uniweb SIA 413.875 €
Uniwersytet Jagiellonski 6.459,36 €
Vector B2B Drug Developing Associação para Investigacao em Biotecnologia 306.020 €
Zora Biosciences Oy 1.234.081 €

Quelle: https://cordis.europa.eu/project/id/848056

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.